News & Views
Assay Ready Cell-Lines Easier to Source
Nov 12 2017
A distributor agreement signed by Gyros Protein Technologies AB (Uppsala, Sweden) will provide its customers in Europe and North America direct access to Euro Diagnostica’s iLite® assay ready cell lines, which are said to help overcome limitations of conventional cell-based assays and improve productivity.
iLite technology is based upon a unique reporter gene assay format that complement those addressed by Gyros Protein Technologies’ Gyrolab™ immunoassays systems, such as pharmacokinetics studies, detection of ADA (anti-drug antibodies) and bioprocess applications. The iLite dual reporter gene format allows for normalisation of the response, eliminating unwanted matrix effects and compensating for differences in cell numbers, to achieve accurate and biologically relevant results. The cells are delivered frozen and assay ready, requiring no culture or maintenance, to enable cost reductions and time savings the company said.
Dan Calvo, CEO and President at Gyros Protein Technologies, said: “The iLite technology is an ideal addition to our offering and is a natural complement to Gyrolab systems. This agreement with Euro Diagnostica further strengthens the position of Gyros Protein Technologies as a key analytical tools provider focused on developing and supplying drug immunogenicity and biologics solutions that increase productivity for customers in the biopharma and biotech industry.”
Dennis Hutchison, CCO of Malmö-based Euro Diagnostica commented: “This distribution agreement is an important step in enabling more researchers to access iLite cell lines, saving costs and improving productivity in cell-based assays.”
Digital Edition
Lab Asia 31.4 August 2024
August 2024
Chromatography Articles - HPLC gradient validation using non-invasive flowmeters Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers Labo...
View all digital editions
Events
Sep 11 2024 Bangkok, Thailand
Sep 11 2024 Bangkok, Thailand
Sep 11 2024 Singapore
Sep 18 2024 Lausanne, Switzerland
Sep 19 2024 Shanghai, China